Incyte Corporation (INCY)
NASDAQ: INCY · IEX Real-Time Price · USD
51.68
+0.50 (0.98%)
At close: Apr 26, 2024, 4:00 PM
51.15
-0.53 (-1.03%)
After-hours: Apr 26, 2024, 7:53 PM EDT
Incyte Employees
Incyte had 2,524 employees on December 31, 2023. The number of employees increased by 200 or 8.61% compared to the previous year.
Employees
2,524
Change (1Y)
200
Growth (1Y)
8.61%
Revenue / Employee
$1,464,203
Profits / Employee
$236,767
Market Cap
11.60B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG & Co. KGaA | 119,845 |
DaVita | 70,000 |
Dr. Reddy's Laboratories | 25,863 |
Bruker | 9,707 |
Exact Sciences | 6,600 |
Natera | 3,293 |
Insulet | 3,000 |
Sarepta Therapeutics | 1,314 |
INCY News
- 4 days ago - Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists - Business Wire
- 16 days ago - Incyte to Report First Quarter Financial Results - Business Wire
- 26 days ago - Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia - Business Wire
- 26 days ago - CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia - GlobeNewsWire
- 4 weeks ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - The Stock Market Is Already Way Up. 8 Stocks That Can Still Outperform. - Barrons
- 6 weeks ago - Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis - Business Wire
- 6 weeks ago - Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa - Business Wire